University of Texas/Texas AM Investment Management Co (UTIMCO)’s Spyre Therapeutics SYRE Stock Holding History

University of Texas/Texas AM Investment Management Co (UTIMCO)’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,827	Closed	-$111K	–	101
2023 Q2	$111K	Hold	9,827	–	–	0.04%	10
2023 Q1	$71K	Hold	9,827	–	–	0.03%	12
2022 Q4	$111K	Hold	9,827	–	–	0.04%	27
2022 Q3	$129K	Hold	9,827	–	–	0.05%	14
2022 Q2	$124K	Hold	9,827	–	–	0.05%	11
2022 Q1	$565K	Hold	9,827	–	–	0.29%	8
2021 Q4	$1.17M	Hold	9,827	–	–	0.53%	13
2021 Q3	$1.95M	Sell	9,827 -956	-9%	-$167K	1.12%	10
2021 Q2	$1.88M	Sell	10,783 -404	-4%	-$73.4K	1.44%	8
2021 Q1	$2.21M	Hold	11,187	–	–	1.3%	9
2020 Q4	$2.2M	Hold	11,187	–	–	2.38%	7
2020 Q3	$1.98M	Hold	11,187	–	–	2.06%	8
2020 Q2	$2.59M	Sell	11,187 -1,719	-13%	-$327K	10%	4
2020 Q1	$1.5M	Hold	12,906	–	–	2.07%	5
2019 Q4	$2.46M	Buy	+12,906	New	+$2.53M	2.63%	5
2019 Q2	$2.3M	Hold	13,411	–	–	2.84%	7
2019 Q1	$2.7M	Hold	13,411	–	–	3.43%	6
2018 Q4	$2.51M	Hold	13,411	–	–	2.71%	7
2018 Q3	$3.21M	Sell	13,411 -216	-2%	-$50.5K	3.97%	4
2018 Q2	$3.6M	Sell	13,627 -7,370	-35%	-$1.81M	1.39%	2
2018 Q1	$5.21M	Hold	20,997	–	–	2.05%	2
2017 Q4	$2.84M	Hold	20,997	–	–	10.96%	5
2017 Q3	$2.59M	Hold	20,997	–	–	6.2%	6
2017 Q2	$2.02M	Hold	20,997	–	–	6.01%	7
2017 Q1	$3.91M	Hold	20,997	–	–	10.21%	2
2016 Q4	$2.28M	Hold	20,997	–	–	6.55%	8
2016 Q3	$3.37M	Buy	+20,997	New	+$2.92M	8.97%	5

Other funds holding SYRE

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO)'s SYRE Position: Q3 2023 in Review

University of Texas/Texas AM Investment Management Co (UTIMCO) sold out of Spyre Therapeutics (SYRE) in Q3 2023, closing a stake of 9,827 shares — an estimated $111K sold.

University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in SYRE in Q3 2016 and held it in 27 quarters. The position peaked at $5.21M in Q1 2018. 29 funds tracked by Wall St. Rank hold SYRE as of Q3 2023.

University of Texas/Texas AM Investment Management Co (UTIMCO) reported no remaining Spyre Therapeutics position as of Q3 2023 after selling out during the quarter.
University of Texas/Texas AM Investment Management Co (UTIMCO) sold 9,827 Spyre Therapeutics shares in Q3 2023, an estimated $111K.
University of Texas/Texas AM Investment Management Co (UTIMCO) first reported a position in Spyre Therapeutics in Q3 2016 and held it in 27 quarters.
University of Texas/Texas AM Investment Management Co (UTIMCO)'s Spyre Therapeutics position peaked at $5.21M in Q1 2018.
29 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2023.

Based on University of Texas/Texas AM Investment Management Co (UTIMCO)'s 13F filing for Q3 2023, filed 9 Nov 2023.